Bortezomib, lenalidomide, and dexamethasone (VRd) is a preferred first-line treatment option for patients with newly diagnosed multiple myeloma. Whether the addition of the anti-CD38 monoclonal ...
Management of Residual Nonretroperitoneal Disease in Postchemotherapy Nonseminomatous Germ-Cell Tumors Transplant-eligible all-comers NDMM patients were profiled for UHiR disease, defined by presence ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback